Multinational medical devices and healthcare firm Abbott Labs (ABT) has reported solid second-quarter 2021 financial results. The Illinois-based company offers nutritional products, branded generic medicines, diagnostics and medical devices. Adjusted earnings per share (EPS) increased 105.3% year-over-year to $1.17, surpassing the Street’s estimates of $1.02. Quarterly sales grew 39.5% year-over-year to $10.2 billion, beating analysts’ expectations of $9.7 billion. Nutrition sales increased nearly 12% to $2.1 billion; Diagnostics sales rose 62.8% to $3.2 billion; Established Pharmaceuticals sales climbed 16.4% to $1.2 billion; and Medical Devices sales surged 51.3% to $3.7 billion. The President and CEO of Abbott, Robert B. Ford, said, “We're achieving very strong growth across our portfolio.
https://www.tipranks.com/news/abbotts-q2-earnings-rise-105-beat-estimates?utm_source=advfn.com&utm_medium=referral
Abbott Laboratories (NYSE:ABT)
Historical Stock Chart
From Oct 2021 to Nov 2021 Click Here for more Abbott Laboratories Charts.
Abbott Laboratories (NYSE:ABT)
Historical Stock Chart
From Nov 2020 to Nov 2021 Click Here for more Abbott Laboratories Charts.